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Summary 
Autocrine-like growth stimulation has previously been 
reported by us in a human malignant glioma cell line, TM-1. In 
the present stud y, the growth factors promoting TM-1 cell growth 
in serum-free medium were investigated by analyzing the medium 
conditioned by growing TM-1 cells. Platelet-derived growth 
factor (PDGF), transforming growth factor (TGF)-a, and 
transforming growth factor (TGF)-� were immunochemically d etected 
in the medium. Although epidermal growth factor (EGF) was not 
detectable in the cond itioned medium, TM-1 cells possessed EGF 
receptors. Exogenously add ed PDGF, TGF-a, and EGF stimulated 
thymid ine incorporation by TM-1 cells in serum-free media. In 
ad dition, antibodies specific for PDGF and TGF-a successfully 
suppressed thymidine incorporation. It is conclud ed that PDGF and 
TGF-a play a stimulatory role for proliferation of TM-1 cells in 
an autocrine manner. TGF-� by itself weakly suppressed thymid ine 
incorporation. However, when ad ded in combination with TGF-a or 
EGF, TGF-� exhibited a cooperative ac·tion in the stimulation of 
thymid ine incorporation. This suggests that multiple growth 
factors produced by malignant glioma cells could promote their 
growth in a cooperative fashion. 
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Introduction 
Sporn and Todaro first pointed out that the constitutive and 
simultaneous production of a growth factor and its receptor 
facilitates the growth of malignant cells. 41 Since then, 
numerous examples of autocrine growt:h of transformed cells have 
been reported.9 , 17 , 2 8, 2 9 , 31, 32 , 37 , 43 
Several stud ies have d emonstratE�d that cultured glioma cells 
produce the c-sis protooncogene product, the B-chain of platelet­
derived growth factor (PDGF) and its specific 
receptors. 9 , lO, l5, l9 , 2 4, 31, 32 Transforming growth factor (TGF)-
a was produced by cultured glioma CE�lls. 31, 37 These growth 
detected in surgically resected glioma factors have also been 
tissues.7 , 15, 18, 2 4, 2 5, 39 EGF receptor gene expression appears 
to be increased in glioblastoma cells. 7 , 8, 2 2 , 49 In ad d ition, 
basic fibroblast growth factor (bFGF) and its receptor are 
prod uced by most human glioma cells.2 8, 42 The expression level 
of these growth factors and their specific receptors correlates 
well with the degree of glioma malignancy, suggesting tho 
occurrence of multiple autocrine loops.6, 7 , 2 2 , 2 4, 2 5, 31, 39 
However, these growth factors producBd by glioma ce.lls m<ly c-1cl. 111 
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cells bearing the specific receptors could be fed by growth 
factors in the serum.48 In add ition, there are often marked 
d ifferences between human glioma cell lines in their production 
of growth factors and response to exogenously ad ded growth 
factors.30 , 47 Therefore, formal proof for autocrine stimulation 
in vitro should be obtained only when it is proved that growth is 
both stimulated by growth factors and retard ed by specific growth 
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factor antibodies. 31 In the strict sense, there was no evidence 
for the occurrence of multiple autocrine loops in human glioma 
cells. 
Transforming growth factor (TGF)-� is a highly ubiquitous 
protein synthesized by most tissues and cell types including 
human glioma cells. 6, 35 Although originally found as 
tumorigenic factor for normal fibroblasts, 5'6 TGF-fi acts as 
bifunctional growth regulator for many normal and transformed 
cell lines, depending upon the growth condition and presence of 
other growth factors. 35 In human glioblastoma cell lines, this 
factor did not affect their growth in monolayer cultures but 
inhibited the anchorage-independent growth with a great 
individual variation in their sensitivity for TGF-�. 12, 14 
Therefore primary effect of TGF-� on the glioma growth still 
remain uncertain. Furthermore, the interactions of TGF-� with 
other growth factors have been an are�a of interest even in the 
limited field for the central nervous system cells. 20 , 38 
In our laboratory, Arai et al. 2 have established a cell line 
(TM-1) from human malignant glioma tissue. TM-1 cells produced 
certain factors which promote growth in the absence of 
exogenously added fetal bovine serum. 2 This study was performed 
to identify the growth promoting factors and to examine the 
response of TM-1 cells to added growth factors. We provide 
evidence for autocrine functions of PDGF, TGF-a, and TGF-� in 
the growth of TM-1 cells. 
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Materials and Methods 
Ce��s and Media A human glioma cell line (TM-1)2 was used. 
TM-1 cells have been serially subcultured over 450 times for the 
past 8 years and expresse glial fibrillary acidic protein, which 
is a reliable marker of glial origin. A human fibroblast cell 
line was prepared from scalp tissue obtained surgically. A 
normal rat kidney fibroblast clone (NRK 49 F) was obtained from 
Riken Gene Bank (Tsukuba, Japan). Eagle's minimal essential 
medium (MEM) supplemented with 10 % fetal bovine serum (FBS), and 
Dulbecco's modified Eagle's medium (DMEM) with 10 % FBS were 
employed to maintain the human cells and NRK 49 F cells, 
respectively, at 37oc under 20 % o2 and 5% co2 in air with 100%  
humidity. The cells were subcultured every 3 to 5 days by 
treating monolayers with 0 . 25% trypsin and 0 . 0 2% EDTA. 
Serum Free Conditioned Hedium and Cel.L Lysa�e Conditioned 
medium was prepared as previously reported. 5, l7 TM-1 cells (2 x 
10 6 cells) growing at logarithmic phase were plated on a 10 0 -mm 
tissue culture dish with a medium composed of an equal volume of 
Ham's Fl2 and DMEM (Fl2/DMEM). FBS was present at a concentration 
of 10% .  After a 24-hour incubation, the cell layer was washed 
twice with Fl2/DMEM and was allowed to grow in Fl2/DMEM for an 
additional 24 hours at which time the serum free medium was 
renewed. The conditioned medium was prepared by two cycles of 
48-hour incubation using F12/DMEM. The collected media was 
centrifuged at 100 , 0 0 0  g for 45 minutes and the supernatant was 
stored at -80 °C until use. The confluent culture of TM-1 cells 
grown in F12/DMEM was lysed with 1% sodium dodecyl sulfate (SDS). 
Aliquots were then used for immunochemical analysis and for 
5 
protein quantitation by the method of Lowry et a1. 23 
Assay for Growth Promotion Activity TM-1 cells (5 X 10 4) 
plated on a 60 -mm plastic culture dish with 4 ml of F12/DMEM 
containing 1% FBS were allowed to adhere for 24 hours. The cells 
were then washed twice with F12/DMEM and further grown in 
F12/DMEM supplemented with 10 �g/ml of protein extracted with 
acetic acid from the conditioned medium (see the Results 
section). The number of viable cells was monitored by trypan 
blue exclusion every 2 days. Cells processed in parallel but 
without the addition of the protein fraction were used as a 
control. 
In another experiment, rates of thymidine incorporation 
into DNA were determined for both TM-·1 cells and human 
fibroblasts grown in F12/DMEM supplemented with the partially 
purified protein fraction. Cells were harvested following a 24 
to 36-hour incubation for labeling. DNA was extracted with 
salt-saturated phenol. Incorporated radioactivity was determined 
by using a liquid scintillation spectrometer. 
Anchorage Independent Growth The colony forming activity of 
NRK 49 F cells was assayed on agar plates consisting of basal and 
upper layers of 0 . 5% and 0 . 3% agar in DMEM containing 10 % FBS.5 
The 0 . 3% agar contained cells and the indicated amounts of 
pr otein fractions from Bio-Gel P60 (see the Results section) and 
was overlaid on the basal agar. The cells were grown for 2 weeks 
at 37°C under 5% co2 in air. Clear colonjes comprisoct of nt 
least 20 cells (Fig. 4A) were counted on a single plate. 
Immunochem.ical. JJ.nal.ysis Aliquots of the Bio-Gel P60 fractions 
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were slot-blotted in duplicate on a nitrocellulose filter. 11 
Half of the blot was treated with goat antibodies specific for 
PDGF (Collaborative Research, Bedford, MA), or TGF-a (Biotope, 
Bellevue, WA). The other half of the blot was treated with a 
control goat Ig (Biotope, Bellevue, WA). The blots were 
incubated with horse radish peroxidase-conjugated anti-goat IgG 
for 1 hour. 
In other experiments, both the acetic acid extract of 
conditioned medium and the cell lysat:e (80 �g protein each) were 
subjected to polyacrylamide gel electrophoresis in the presence 
of sns21 and separated proteins were electrophoretically 
transferred to a nitrocellulose filter. The proteins were treated 
either with a goat antibody for TGF-ot or PDGF, or with a rabbit 
antibody raised against TGF-� (King Brewing, Japan) or EGF 
(Wakunaga Pharmaceutical, Japan). [125I]Anti-rabbit Ig F(ab' )2 
(Amersham, Japan) was employed to locate the factors according to 
the method of Towbin et a1.45 When goat antibodies were used, a 
rabbit anti-goat IgG (Jackson Immuno Research Lab, Baltimore, MD) 
was employed prior to treatment with the radioactive antibody. 
Binding of �25I-Labe�ed EGF to TH-1 Ce��s Intact TM-1 cells 
were examined for the binding of 125I-EGF as described by 
Westphal et a1.46 TM-1 cells were seeded at a density of 1 X 
10 5 cells on a 35-mm culture dish with MEM supplemented with 10 % 
FBS and were grown for 4 days to confluency. The cells were 
washed at room temperature three times with phosphate buffered 
saline containing 1 mg/ml of bovine serum albumin, 0 . 0 1  mg/ml 
Dishes in 
duplicate received 1 ml of binding buffer to which 1 ng of 125I-
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EGF (140 , 0 0 0  cpm/1 ng, Amersham, Japan) and EGF (Collaborative 
Research, Bedford, MA) at final concentrations ranging from 0 to 
10 0 ng/ml had been added. EGF and the cells were incubated for 
2 hours at room temperature and the binding was terminated by 
five washes with ice-cold binding buffer. 
of 1% SDS were examined for radioactivity. 
Cells lysed in 1 ml 
Nonspecific binding 
was defined as the amount of 125r-EGF bound in the presence of 
50 0 -fold excess EGF. Scatchard analysis40 was conducted to 
calculate the number of EGF receptors per cell and the Kd value 
for EGF. 
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Results 
Partial_ Purifica-tion of Factors Requ_jlred for -the TH-L CeLL Growtll 
from the TH-L CeLL-Derived Condi-tionE� Hedium As previously 
reported by Arai et a1, 2 TM-1 cell-derived conditioned medium 
stimulates the proliferation of TM-1 cells in the absence of 
fetal bovine serum. To identify the factors in the medium, an 
aliquot of this conditioned medium was dialyzed against 0 . 17 M 
acetic acid and lyophilized. 5 As shown in Fig. 1, a fraction 
extracted from the lyophilized residue with 1. 0 M acetic acid 
(acetic acid extract) exhibited a growth promoting activity for 
TM-1 cells. 
Along with the cell growth, thymidine incorporation into DNA 
was stimulated in both the TM-1 cells and human fibroblasts, to 
which the acetic acid extract was added (Fig. 2). These results 
confirmed the previous conclusion that TM-1 cells could produce 
and excrete certain factor(s) necessary for the proliferation of 
TM-1 cells. 2 Further, it is clear that thymidine incorporation 
can be used to screen for the factors required for this 
autocrine-like growth promotion. In the present study, we 
attempted to characterize the factors on the basis of both 
biological and immunochemical properties. 
Five milliliters of aliquots of the acetic acid extract 
(1, 250 �g protein) were fractionated at 4oc on a Bio-Gel P60 
column (10 0 -200 mesh, 2. 5 x 9 0  em) equilibrated with 1 M  acetic 
acid as described by De Larco et a1. 5 Most proteins were 
distributed in fractions corresponding to molecular mass larger 
than approximately 30 kDa. Despite the negligible absorbance at 
280 nm, all fractions were separately lyophilized and each 
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samples was dissolved in 4 ml of F12/DMEM. Aliquots from every 3 
fractions were combined. This combined fraction still contained 
the growth promoting activity for TM-·1 cells (data not shown). 
However, the activity of the combined fraction disappeared by 
treatments with either trypsin or dithiothreitol (data not 
shown). These results suggest that polypeptides is responsible 
for the growth promoting activity. 
Bio-Ge� P60 Fractions StimuLated Thynridine Incorporation by 
Different Types of Ce��s and Anchora�re Independent Growth of NRK 
49F Ce��s The Bio-Gel P60 fractions were examined for 
mitogenic activity by measuring the rates of thymidine 
incorporation by TM-1 cells and human fibroblasts (Fig. 3 A and 
B). The major activity for TM-1 cells was found in fractions 
corresponding to molecular mass from 11 to 7 kDa (fractions 36-43 
in Fig. 3 A). A similar profile was found in experiments 
using human fibroblasts, except that fractions 22-25 had a 
greater stimulation of thymidine incorporation into human 
fibroblasts compared to TM-1 cells. The presence of multiple 
peaks of activity in the profiles suggested the presence of 
multiple factors with similar biological activities. 
As can be seen in Fig. 4 A, NRK 4 9F cells formed a clear 
colony in the presence of the combined eluate fractions. This 
activity was mainly distributed in fractions 37 -4 7 ,  which 
contained peptides of approximately 7 kDa (Fig. 4 B). These 
results suggested that TGF-a was a possible factor in these 
fractions.1'5 
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Immunochemica1 Detection of Po�ypeptJ[des Resemb�ing PDGF, TGF-a, 
and TGF-� Anti-PDGF antibody gave a clear signal for the blot 
of fraction 22 (Fig. 5 A). It should be noted that thymidine 
incorporation by human fibroblasts was stimulated by the addition 
of fractions 22-25 (Fig. 3 B). A weak but detectable stimulation 
of thymidine incorporation was also observed by adding these 
fractions to the TM-1 cell culture (Fig. 3 A). Furthermore, 
both the TM-1 cell lysate and the serum-free culture medium of 
these TM-1 cells contained a polypeptide that reacted with the 
same antibody preparation (Fig. 5 B). Molecular mass of this 
polypeptide appeared to be 30 kDa which matches that reported for 
PDGF. 29 , 32 Therefore, the results indicate that TM-1 cells 
might produce and excrete PDGF into the serum-free medium. 
On the other hand, anti-TGF-a antibody gave signals on the 
blots for fractions 42, 43, and 45 (Fig. 5 A). These fractions 
exhibited higher stimulation of thymidine incorporation by TM- 1 
cells and human fibroblasts. As mentioned above, these fractions 
also stimulated colony formation of NRK 49 F cells. The size of 
polypeptide, estimated by gel filtration, was similar to that 
of TGF-a. 1'5 These observations imply that TGF-a was present in 
the TM-1 conditioned medium. 
In addition to these two growth factors, an immunoblot 
analysis demonstrated that the conditioned medium and the TM-1 
cell lysate contained a polypeptide reactive to anti-TGF-B 
antibody (Fig. 5 B). Unlike PDGF and TGF-�, antibodies for TGF-a 
or EGF failed to produce significant signals. 
EGF Receptors on TH-� Ce��s While EGF was not demonstrated 
immunochemically, intact TM-1 cells grown in MEM supplemented 
11 
with 10 % FBS bound 125I-labeled EGF. As shown in Fig. 6 A, the 
binding was saturable with the ligand and was competitive with 
native EGF. A scatchard plot40 of the� binding data indicated 5.9 
X 10 5 receptors per cell, a value approximately 10 times larger 
than that for untransformed cells. 8 The dissociation constant 
was calculated to be 6. 8 X 10-10 M with a single class of 
affinity for EGF (Fig. 6 B). These values confirmed earlier 
observations made on a human glioma line, SF264 by Harsh et a1. 10 
S�im�a�ion of Hi�ogenic Activity of TH-1 Ce11s by Various Growth 
Factors Exogenous1y Added To know whether the production of 
these growth factors by TM-1 cells promoted growth, TM-1 cells 
grown in the absence of FBS were examined for the response to 
exogenously added growth factors. As shown in Fig. 7 B, TM-1 
cells incorporated more thymidine when a concentration of EGF 
near the Kd value was exogenously ad ded. Therefore, it appears 
that EGF receptors detected by the binding of radioactive EGF 
respond to added EGF. Similarly, exogenously added PDGF 
maximally enhanced thymidine incorporation at concentrations near 
the Kd values of PDGF receptor (1o-10M)30 (Fig. 7 A). Stimulation 
was also observed by the addition of TGF-a. Only TGF-B 
(Biomedical Technologies Inc, Stoughton, MA), even at 
concentration 6-7 times higher than the reported Kd value of the 
TGF-� receptors (6. 5 x lo-11M), 13 did not stimulate thymidine 
incorporation. 
Synergism Shawn by the Simul.taneous Addition of TGF-B and one of 
PDGF, TGF-a, and EGF Table I shows the synergistic 
stimulation of thymidine incorporation in TM-1 cells grown in 
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serum free medium to which TGF-� was added in combination with 
either PDGF, TGF-a, or EGF. PDGF, TGF-a, and EGF added alone 
stimulated thymidine incorporation 1.5-, 1.8-, and 2.4-fold. 
TGF-� at 120 pM inhibited thymidine incorporation to 92% of the 
control. However, in combination wit:h PDGF, TGF-� increased 
thymidine incorporation by 1.1-fold in comparison to that found 
when PDGF alone was added. This synergism was more clearly 
demonstrated in the presence of TGF-a and TGF-�. In this case, 
the extent of the stimulation was approximately 1.3-fold that 
found when TGF-a alone was present. 
observed for TGF-� and EGF. 
A similar synergism was 
ImmunoLogic Suppression of Thymidine Incorporation Table II 
indicates that an antibody specific for PDGF (Mochida Pharma­
ceutical, Japan) suppressed thymidine incorporation. At high 
concentrations this antibody inhibite�d the thymidine 
incorporation activity to 4 6% of the control value. Although 
anti-TGF-a antibody inhibited this activity to 82% of the 
control activity, the combined use of these two antibodies 
increased the degree of inhibition. Since under similar 
conditions, control Ig preparation did not affect thymidine 
incorporation, these results indicate� that the endogenously 
produced PDGF and TGF-a exhibit growth promoting activity on 
TM-1 cells in the serum-free condition. 
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Discussion 
In the present study, we used immunochemical techniques to 
demonstrate that the serum-free medium conditioned by growing 
TM-1 cells contains PDGF, TGF-a, and TGF-�. The addition of 
PDGF or TGF-a to the serum-free culture medium increased 
thymidine incorporation by TM-1 cells. In addition, thymidine 
incorporation by TM-1 cells was suppressed by antibodies to PDGF 
and TGF-a. These results clearly support the hypothesis that 
TM-1 cells produce these growth factors which are utilized for 
growth promotion in an autocrine manner. 
While EGF was not detected in the conditioned medium, TM-1 
cells had EGF receptors whose number and Kd were similar to those 
reported for a human malignant glioma cell line. 10 These 
receptors seem to be functional because exogenous EGF stimulated 
thymidine incorporation. Since TGF-n and EGF may share the 
identical receptor molecule at practically indistinguishable 
affinities for the two ligands, 3 the EGF receptors on TM-1 
cells could function to promote growth by endogenous TGF-a. 
TGF-� appears to have a more complex role in growth 
regulation. In our experiments, TGF-� weakly suppressed the 
thymidine incorporation by TM-1 cells but it increased that 
beyond the activity shown by TGF-a or EGF alone. Helseth et 
al, 12, 14 described that the primary effect of TGF-� on the 
glioma growth seemed to be inhibitory. In another experiment, 
exogenous TGF-�1 and TGF-�2 were growth-inhibitory among the low 
grade gliomas but stimulated the proliferation of most 
hyperdiploid glioblastoma cells. 16 It is well known that TGF-� 
may act as a growth inhibitor for many untransformed cell 
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types. 26, 35 Malignantly transformed counterparts of these cells 
often decrease sensitivity to growth inhibition. 35 For example, 
TGF-� inhibited growth of rat astroblasts but it stimulates the 
growth of transformed C6 rat glioma cells.38 Loss of this 
negative growth control by TGF-� may be one mechanism 
contributing to their uncontrolled growth of tumor cells. 4, l6, 35 
The mechanisms responsible for the cooperative action of TGF-� 
shown in our experiment is unknown. Similar action was found in 
rat astroblasts, in which TGF-B act as growth inhibitor, but it 
potentiates the mitogenic effect of bFGF.20 Several studies 
have suggested that these cooperative action might result from 
increased expression of the receptor or activation of signal 
transduction.16, 26, 36 
Human glioblastoma cells have bE�en shown to secrete a potent 
immunosuppressive factor, called glioblastoma-derived T-cell 
suppressor factor, which has been found to be identical to TGF-
�2. 18, 27 , 50 In view of these unique actions of TGF-�, 
production of TGF-B by TM-1 cells contributes to a 
microenvironment more suitable for their own growth. 
The combined results lead us to the convincing conclusion 
that TM-1 cells possess multiple loops for autocrine growth 
promotion. Furthermore, if the difference in the mitogenic 
activity determined by the amounts of thymidine incorporated in 
vitro indicates the difference in the� actual growth rate of 
tumor cells in vivo, it is worth mentioning that production of 
multiple growth factors could enhance� their growth promotion of 
malignant glioma cells through a cooperative action. The study 
15 
of the interaction of growth factors will provide important 
insights into the mechanisms of the aberrant growth of 
malignant glioma cells. 
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Table I. Stimulation of thymidine incorporation by growth 
factors that were exogenously added to the TM-1 cell culture. 
Thymidine incorporation was assayed for TM-1 cells grown in 
F12/DMEM containing the growth factoi�s indicated. The 
radioactivity incorporated was determined in triplicate. The 
difference in thymidine incorporation measured in the system to 
which TGF-� was added in combination with TGF-a or EGF were 
confirmed against that measured with each growth factors alone by 
unpaired Student's t-test. 
Growth factor added r:l�hymidine incorporated 
(% of control) 
A. none 100 a 
TGF-� (120 pM) 9 2  
PDGF (330 pM) 145 
TGF-a (4, 50 0 pM) 17 7 
EGF (450 pM) 244 
B. PDGF (330 pM) + TGF-� (120 pM) 160 
TGF-a (4, 500 pM) + TGF-� (120 pM) 224b 
EGF (450 pM) + TGF-� (120 pM) 29 5b 
a The control value, 8, 0 0 0  cpm/104cells, was referred to 10 0 % .  
b p<0 . 0 5  
25 
Table II. Suppression of thymidine incorporation by anti-PDGF or 
anti-TGF-a antibodies. Either anti-PDGF or anti-TGF-a antibody 
was added to the TM-1 cell culture in F12/DMEM. Thymidine 
incorporation was assayed as described in Materials and Methods. 
The statistical significance was examined by unpaired Student's 
t-test. 
Antibody added 
none 
A. anti-PDGF ( 2 �g/ml) 
(20 �g/ml) 
B. anti-TGF-a(1:100 0 )  
( 1: 100 )  
c. anti-PDGF (20 �g/ml) 
anti-TGF-a(1:100 )  
a p<0 .0 1 
b p<0 . 0 5  
with 
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Thymidine incorporated 
(% of control) 
10 0 
7 1  
46a 
88 
82b 
34a 
Figure l£gends 
Fig. 1. The growth promotion for TM-1 cells by a protein 
fraction extracted with acetic acid from the serum-free medium 
conditioned by the growing TM-1 cells. TM-1 cells subcultured 
in F12/DMEM were grown in the presence (open circle) or absence 
(filled circle) of 10 �g of protein extracted from the 
conditioned medium with 1 M acetic acid. The number of cells per 
dish was determined by trypan blue exclusion in triplicate at the 
time indicated. Each value represents the mean value with 
standard error. 
Fig. 2. The stimulation of the thymidine incorporation by TM-1 
cells and human fibroblasts in the presence of the acetic acid 
extract from the conditioned medium. TM-1 cells and human 
fibroblasts were cultured in the serum-free medium to which the 
various amounts of the acetic acid-extracted fraction and 
[3H]thymidine (0 .5 �Ci) had been supplemented. The cells were 
harvested after incubation for 24 to 36 hours and their DNA was 
extracted with salt-saturated phenol. Radioactivities 
incorporated into DNA of TM-1 cells (filled circle) and the human 
fibroblasts (open circle) were determined. 
Fig. 3. Elution profiles of the thymidine incorporation activity 
on a Bio-Gel P60 column. The acetic acid-extract (1, 250 �g in 
protein amount) was partially purified on a Bio-Gel P60 column 
(2.5 X 9 0  em) equilibrated with 1 M acetic acid. The eluates in 
each fraction were examined for absorbance at 280 nm (dotted 
27 
line) and then lyophilized. The lyophilized samples were 
dissolved in F12/DMEM. One third of each solution was added to 
F12/DMEM for TM-1 cells (A) and for human fibroblasts (B). 
Thymidine incorporation (solid line) was determined as shown in 
the legend for Fig. 2. 
Fig. 4. Elution profile of the stimulation activity of the 
anchorage independent growth of NRK 49 F fibroblasts. 
A. A microscopic photograph of a NRK 49 F colony on a soft agar 
plate. 
B. The acetic acid-extract from the conditioned medium was 
developed on a Bio-Gel P60 column under the same condition as 
employed for chromatography in Fig. 3. An aliquot of each 
fraction was assayed for stimulation of anchorage independent 
growth of NRK 49 F cells. 
Fig. 5. Immunochemical detection of PDGF, TGF-a, and TGF-�. 
A. PDGF and TGF-a in the eluate from a Bio-Gel P60 column. 
The acid-extractable fraction was partially purified on the 
column. Aliquots (100 �1) of each fraction that exhibited 
stimulation of thymidine incorporation or soft agar colony 
formation were slot-blotted on a nitrocellulose filter followed 
by treatment with antibodies specific for PDGF (upper panel) or 
TGF-a (lower panel). 
B. Intra- and extracellular PDGF and TGF-�. TM-1 cells 
grown in the serum-free F12/DMEM were separated from the 
conditioned medium. Both the cell lysate (C) and an aliquot 
28 
of the conditioned medium (M) were denatured with a mixture of 
2% SDS and 5% 2-mercaptoethanol. The denatured proteins were 
separated by electrophoresis on a 80S-polyacrylamide gel and were 
incubated with antibodies specific for PDGF (left ) or TGF- � 
(right ). [125r]-Labeled secondary antibody was used for detection 
by autoradiography. 
Fig. 6. The specific binding of EGF on the intact culture of 
TM-1 cells. A. The binding of [125r]-EGF to TM-1 cells in the 
presence of variable amounts of unlabeled EGF. A set of the 
confluent culture was subjected to binding assay as described 
under the Materials and Methods. Radioactivity bound to the 
cells was expressed as percent of total radioactivity. 
B. Scatchard plot of EGF binding. The data of A were plotted 
according to the method of Scatchard.40 
Fig. 7 .  Effects of exogenously added growth factors on thymidine 
incorporation by TM-1 cells. [3H]Thymidine incorporation by TM-1 
cells grown in F12/DMEM was examined in the presence of PDGF (A), 
EGF (B), TGF-a(C), or TGF-� (D) which were exogenously added at 
concentrations indicated. Radioactivity incorporated was 
determined as described in the legend for Fig.2. 
29 
100 
..-.. 50 
.!: 
en 
·-
"'0 
.......... 
.q 
0 
� 
>< 
...._... 
J... 
Q) 
.0 
E 10 
:l 
t: 
Q) 
(.) 5 
0 I I I I I I 
0 2 4 6 
I I I I I 
8 10 
Days after addition of protein 
Fig. 1 
....-.... 
.c 
en 
·-
"0 
......... 
E 
fr 4 
>< 
� 
0 
.,.... 
......_., 
c 3 
0 
+J 
ca 
1-
g_ 2 1-
0 
u 
c 
Q) 
c 
"0 
E 
>­
.c 
+J 
I 
J: 
1 
0 
0 10 20 
Added protein factor ([Ll9 I dish) 
Fig. 2 
A
. 
..-
0.
1 
� 
• i E c 0 co N -ro
 
o.
o5
 
Q) u c: ro .0
 
..
..... 
J 
0 (/) ..c
 
<t
 
Vo
 
29
kD
a 
12
kD
a 
t 
t 
t 
• . . .. .. ..
 
..
 
..
 
..
 
'
I
 
..
 
.
.
 .. 
A 
:-
: 
� 
' 
� 
llJIJbJ
V� 
15
 
20
 
25
 
30
 
35
 
• I 40
 
6.
5k
D
a 
1 
-
t 
..
......... 
c
 
50
0 
0 ..
..... 
m
 
..
..... 
::
:::-
0 
0 
8 
0 
c 
u 
·-
-
30
0 
Q) 
0 
.::
 �
 
'0
-
/lA 
4 0
0 
e-
� 
v
 
• 
�
� 2 oo 
I 
I 
I 
-
-
-1
00
 
� 
45
 
50
 
55
 
M
 
Fr
ac
tio
n 
nu
m
be
r 
Fi
g.
 
3 
..
..-.. � i - E
 c: 0
 
co
 
N
 
�
 
m
 � c: ro .0 "- 0 (/) .0 <t 
0.
1 
0.
05
 B
. Vo
 
29
kD
a 
t 
t 
• . 
12
kD
a 
t 
6.
5k
D
a 
t 
50
0 
T c: 0 - �--
. � I�
 � N
 \ 
c : l l 
�1
�
 
w 
-·
to! 
o
�
 
..
 ·�U
 1 
1 
�
lao
± 
15
 
20
 
25
 
30
 
35
 
40
 
45
 
50
 
55
 
M
 
Fr
ac
tio
n 
nu
m
be
r 
C'J 0 :X� � <0 
C'J 0 :X__.. N 
C'J 0 
�__.. N 
g� 
co 0 0 
or-
(s11a:> cO� x l 1 ·au) 
. 
<( 
llO lO 
0 lO 
';f 
0 ..q-
lO M 
lO 
N 
0 N 
lO 
or-
0 tO lO 
saiUO!O:> Je6e IJOS 
.... <U .c 
E :J c: c: 
0 
:zj u C'J .... u. 
bf) 
·rl 
W-. 
A. 
Fr. No. 
anti-PDGF Ab 
controllg 
Fr. No. 
anti-TGF-a Ab 
control lg 
B. 
c M 
PDGF 
_/ 30 kDa 
25 kDa 
Fig. 5 
47 48 
_I I 
C M 
TGF-B 
0 
� ,.-........ 
(/) -
-
'U Q) 
c: 0 
LO 
::J<.O 
oo 0 m,... 
LL:::: 
(!} 0 
UJ E 
a. 
..._... 
� M C\1 � 0 
0 0 0 0 
aaJ.::I 1 punoa 
. 0 <( 0 
0 
� 
0 ,.-........ 
0 E � 
........... 
C) 
c: 
...._.. 
0 lL 
� G 
UJ 
(o1) .:lt:"'\3-1 JO 6U.IPU!q OI.J.IOads 10 v 
Sl� 
\() 
. 
bO ·rl 
U; 
c: 15 0 ;; ca(j) 
I- -
o­
a.Cl) 
I- 0 10 
8o 
c:,... 
......... 
� -E 
·- a. 5 
-c 0 
·-
E >< �co 
....,,... 
I ___., 0 
J: 
(f) 
c: 
0 
·-
..... ca(j) 
I- -
o­
a.C1> 
I- 0 
8b 
c:,... 
......... 
� E 
·- a. 
-c 0 
·-
E >< >aM 
-'=o 
....,,... 
I ___., 
:I: 
� 
20 
15 
10 
5 
0 
A. 
PDGF (pM) 
C. 
TGF-a (pM) 
Fig. 7 
c: 
0 
c 
0 
·-
..... CU(j) 
... _ &.Cii 
20 
15 
... 0 
8 "b 10 
c ,.... 
·- ......... 
� E 
·- a. 5 
-c 0 
·-
E >< 
�� .cO 
,... �___., 0 
:I: 
" 
B. 
EGF (pM) 
D. 
TGF-B (pM) 


